OakChart

Arbutus Biopharma Corp

ABUSHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:00 AM ET

4.08+0.05 (1.24%)
2026-11-13 13:04 CET
Market cap
$625.43M
Revenue, TTM
181.49 USD m
Net income, TTM
219.91 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
1.12
Price / earnings
3.64
Compare

Price

ABUS against its 20, 50 and 200-day averages
Terms2050200BeatMiss
Patternshover a marker to name it
RS 15Sales 1.00Price0.390.683.504.004.505.005.509.1M18.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ABUSclose 4.0820-day 4.0650-day 4.46200-day 4.484.0852w high 5.4552w low 3.5052-week range, not 6 months

25.1% under the 52-week high of 5.45 on 21 Aug 2026. 52-week low 3.50 on 2 Feb 2026. Last 15 sessions, 25.3% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Setup. RS line 15
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: EPS Growth Next Year: High (>25%)
Quality 5 of 5
Value 3 of 4 — fails: P/B: Under 2
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%)
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

ABUS
52-week range, 30% of the way up
3.505.45

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

IndexRUT
Employees19
IPOJul 23, 2007
Beta0.81
ATR, 14d0.21
Rel volume0.01
Short float12.64%
Insider own20.55%
Inst own65.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$625.43M
Enterprise Value291.25M
Income219.91M
Sales181.49M
Book / share0.43
Cash / share2.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees19
IPOJul 23, 2007

Ratios

Price / earnings3.64
Forward price / earnings-
Price / earnings / growth-
Price / sales3.45
Price / book9.48
Price / cash1.85
Price / free cash flow-
Value / cash profit2.00
Value / sales1.60
Quick Ratio1.40
Current Ratio1.40
Debt / equity0.04
Long-term debt / equity0.03
Options and shortYes / Yes

Earnings

Earnings / share1.12
Earnings next year-0.08
Earnings next quarter-0.02
Earnings this year535.29%
Earnings next year-110.81%
Earnings growth, 5 years-
Past earnings growth27.58% 29.45%
Past sales growth-28.80% 15.29%
Earnings vs last year608.48%
Sales vs last year1142.57%
Earnings vs last quarter832.92%
Sales vs last quarter-43.48%
EarningsNov 10 BMO
Surprise1393.10% -70.10%

Ownership

Insiders own20.55%
Insider trades0.00%
Institutions own65.27%
Institution trades-6.31%
Return on assets100.55%
Return on equity269.59%
Return on capital247.85%
Gross Margin99.98%
Operating margin80.14%
Profit Margin121.17%
20-day average0.44%
50-day average-8.53%
200-day average-8.94%

Technical

Shares out199.28M
Shares floating157.40M
Short / float12.64%
Short ratio3.92
Short interest19.89M
52-week high5.45 -25.1%
52-week low3.50 +16.6%
Volatility5.62% 4.53%
Average range0.21
Strength index48.13
Market sensitivity0.81
Relative volume0.01
Avg Volume5.08M
Volume1,592

Performance

Perf Week11.63%
Perf Month-4.90%
Perf Quarter-13.38%
Perf Half Y-3.77%
Perf YTD-15.18%
Perf Year-10.53%
Perf 3Y127.93%
Perf 5Y17.58%
Perf 10Y45.71%
Recommendation1.00
Target Price5.50
Prev Close4.03
Price4.08
Change %1.24%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Feb 02, 2022UpgradeJefferiesHold → Buy$5+22.5%
Feb 25, 2021InitiatedJefferiesHold$5+22.5%
Dec 17, 2020InitiatedH.C. WainwrightBuy$10+145.1%
Jul 27, 2020ResumedJMP SecuritiesMkt Outperform$10 → $8+96.1%
Jul 24, 2020DowngradeRobert W. BairdOutperform → Neutral
May 19, 2020UpgradeWedbushNeutral → Outperform
Mar 06, 2020UpgradeChardan Capital MarketsNeutral → Buy$5+22.5%
Feb 20, 2020InitiatedRobert W. BairdOutperform$8+96.1%
Feb 05, 2020UpgradeJMP SecuritiesMkt Perform → Mkt Outperform$10+145.1%
Oct 07, 2019ReiteratedB. Riley FBRBuy$7 → $3-26.5%

Peers

Mkt cap
TickerCompanyMkt cap
ASMBAssembly Biosciences Inc410.88M
VIRVir Biotechnology Inc1.79B
ARWRArrowhead Pharmaceuticals Inc6.66B
ALGSAligos Therapeutics Inc13.96M
ENTAEnanta Pharmaceuticals Inc326.20M
ARCTArcturus Therapeutics Holdings Inc239.22M
AVIRAtea Pharmaceuticals Inc338.08M
SLNSilence Therapeutics Plc ADR1.23B
ALNYAlnylam Pharmaceuticals Inc21.17B
COCPCocrystal Pharma Inc19.07M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Androski LindsayPresident and CEOSep 18 '26Option Exercise3.30126,864418,407154,864Sep 23 08:32 PM
Nguyen TuanChief Financial OfficerSep 18 '26Option Exercise3.57293,1001,047,646366,600Sep 23 08:31 PM
Sawhney RogerDirectorSep 18 '26Option Exercise3.88131,333509,572131,333Sep 23 08:31 PM
Beardsley Robert ADirectorSep 18 '26Option Exercise3.82131,333502,218131,333Sep 23 08:31 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWMiShares Russell 2000 Index FundAUM: 77.86B
XBIState Street SPDR S&P Biotech ETFAUM: 10.59B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
IBBiShares Biotechnology ETFAUM: 11.39B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
JSMLJanus Henderson Small Cap Growth Alpha ETFAUM: 382.20M
SCHASchwab U.S. Small-Cap ETFAUM: 22.44B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.54B

News

latest 14 of 200

Quarterly earnings

2026Q3 EPS 0.300 beat -0.023, from -0.040 a year earlier. Sales 0.30 missed 1.00, from 0.53 a year earlier
EPS
0.8700-0.1302024Q4 EPS -0.070 against -0.08024Q42025Q1 EPS -0.130 against -0.10425Q12025Q2 EPS 0.010 against -0.04825Q22025Q3 EPS -0.040 against -0.03025Q32025Q4 EPS -0.010 against -0.03525Q42026Q1 EPS 0.870 against -0.03026Q12026Q2 EPS -0.030 against -0.02026Q22026Q3 EPS 0.300 against -0.02326Q3
Sales, USD millions
179.1302024Q4 sales 1.57 against 1.5624Q42025Q1 sales 1.76 against 1.5925Q12025Q2 sales 10.74 against 1.5925Q22025Q3 sales 0.53 against 1.2725Q32025Q4 sales 1.05 against 0.6125Q42026Q1 sales 179.13 against 0.7526Q12026Q2 sales 1.01 against 0.7026Q22026Q3 sales 0.30 against 1.0026Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-10 08:300.300-0.0230.3000.301.00EPS -1393.1% · sales -70.1%vs 2025Q3, year-ago quarter · EPS -850.0% · sales -43.5%1Open -0.27% vs SPY -0.63%. Close +2.69% vs SPY -0.37%
2026Q2ended 2026-06-302026-08-12 08:30-0.030-0.020-0.0261.010.70EPS +50.0% · sales +44.9%vs 2025Q2, year-ago quarter · EPS -400.0% · sales -90.6%1Open -1.71% vs SPY +0.54%. Close -1.71% vs SPY +0.25%
2026Q1ended 2026-03-312026-05-13 08:300.870-0.0300.869179.130.75EPS -3000.0% · sales +23783.5%vs 2025Q1, year-ago quarter · EPS -769.2% · sales +10054.5%2Open +4.18% vs SPY +0.04%. Close 0.00% vs SPY +0.56%
2025Q4ended 2025-12-312026-03-23 08:30-0.010-0.035-0.0201.050.61EPS -71.5% · sales +71.0%vs 2024Q4, year-ago quarter · EPS -85.7% · sales -33.2%2Open +2.83% vs SPY +1.46%. Close +4.25% vs SPY +1.05%
2025Q3ended 2025-09-302025-11-13 08:30-0.040-0.030-0.0400.531.27EPS +33.3% · sales -58.2%vs 2024Q3, year-ago quarter · EPS -60.0% · sales -60.5%4 EPS · 3 salesOpen -1.24% vs SPY -0.42%. Close -5.79% vs SPY -1.66%
2025Q2ended 2025-06-302025-08-06 08:300.010-0.0480.01310.741.59EPS -121.1% · sales +575.0%vs 2024Q2, year-ago quarter · EPS -109.1% · sales +522.2%4Open +0.88% vs SPY +0.17%. Close +1.76% vs SPY +0.77%
2025Q1ended 2025-03-312025-05-14 08:30-0.130-0.104-0.1291.761.59EPS +25.0% · sales +10.6%vs 2024Q1, year-ago quarter · EPS +30.0% · sales +15.1%5Open -1.25% vs SPY +0.17%. Close -0.94% vs SPY +0.13%
2024Q4ended 2024-12-312025-03-27 08:30-0.070-0.080-0.0661.571.56EPS -12.5% · sales +0.7%vs 2023Q4, year-ago quarter · EPS -41.7% · sales -26.5%5Open 0.00% vs SPY -0.25%. Close -2.39% vs SPY -0.27%
2024Q3ended 2024-09-302024-11-06 08:30-0.100-0.094-0.1041.341.86EPS +6.4% · sales -28.0%vs 2023Q3, year-ago quarter · EPS -16.7% · sales -71.3%5Open -2.78% vs SPY +2.17%. Close -1.01% vs SPY +2.49%
2024Q2ended 2024-06-302024-08-01 08:30-0.110-0.096-0.1051.731.77EPS +14.6% · sales -2.3%vs 2023Q2, year-ago quarter · EPS +10.0% · sales -62.9%5Open -3.45% vs SPY +0.32%. Close +1.06% vs SPY -1.42%
2024Q1ended 2024-03-312024-05-02 08:30-0.100-0.110-0.1021.532.71EPS -9.1% · sales -43.6%vs 2023Q1, year-ago quarter · EPS 0.0% · sales -77.1%4Open -1.86% vs SPY +0.76%. Close -0.37% vs SPY +0.94%
2023Q4ended 2023-12-312024-02-29 08:30-0.120-0.116-0.1152.144.78EPS +3.4% · sales -55.3%vs 2022Q4, year-ago quarter · EPS -7.7% · sales -65.7%5Open -0.35% vs SPY +0.36%. Close -2.78% vs SPY +0.36%
2023Q3ended 2023-09-302023-11-07 08:30-0.120-0.112-0.1204.664.75EPS +7.1% · sales -1.9%vs 2022Q3, year-ago quarter · EPS 0.0% · sales -21.7%5-
2023Q2ended 2023-06-302023-08-03 08:30-0.100-0.112-0.1034.656.18EPS -10.7% · sales -24.7%vs 2022Q2, year-ago quarter · EPS 0.0% · sales -67.3%5-
2023Q1ended 2023-03-312023-05-04 08:30-0.100-0.136-0.1016.696.04EPS -26.5% · sales +10.8%vs 2022Q1, year-ago quarter · EPS -9.1% · sales -46.8%5-
2022Q4ended 2022-12-312023-03-02 08:30-0.130-0.134-0.1426.256.18EPS -3.0% · sales +1.2%vs 2021Q4, year-ago quarter · EPS -13.3% · sales +94.8%5-

Annual earnings

2025FY EPS -0.170 beat -0.188, from -0.380 a year earlier. Sales 14.08 beat 13.63, from 6.17 a year earlier
EPS
0.0000-2.8902018FY EPS -1.210 against -1.18420182019FY EPS -2.890 against -2.72820192020FY EPS -1.000 against -0.98020202021FY EPS -0.830 against -0.86220212022FY EPS -0.460 against -0.45220222023FY EPS -0.440 against -0.43620232024FY EPS -0.380 against -0.38820242025FY EPS -0.170 against -0.1882025
Sales, USD millions
39.0202018FY sales 5.90 against 5.3320182019FY sales 6.01 against 11.1920192020FY sales 6.91 against 6.5220202021FY sales 10.99 against 10.6820212022FY sales 39.02 against 38.9620222023FY sales 18.14 against 20.7820232024FY sales 6.17 against 6.1820242025FY sales 14.08 against 13.632025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2029FYestimate-0.340--173.5312.00
2028FYestimate--0.140--55.95-
2027FYestimate--0.080--4.10-
2026FYestimate-0.740--182.25.51
2025FY-0.170-0.188-0.17014.0813.63-
2024FY-0.380-0.388-0.3776.176.18-
2023FY-0.440-0.436-0.43918.1420.78-
2022FY-0.460-0.452-0.46039.0238.96-
2021FY-0.830-0.862-0.83210.9910.68-
2020FY-1.000-0.980-1.0006.916.52-
2019FY-2.890-2.728-2.8886.0111.19-
2018FY-1.210-1.184-1.2145.905.33-
2017FY-1.560-1.314-1.56010.708.78-
2016FY-7.240-4.335-7.2401.502.02-
2015FY-1.340-1.533-1.34024.9019.78-
2014FY-1.764-1.577-1.76414.9714.57-
2013FY-0.828-0.690-0.93015.5314.35-
2012FY-0.897-0.4302.08914.1714.37-
2011FY-0.864-0.913-0.86416.3516.60-
2010FY-1.208-1.022-1.20821.4921.62-

Quarterly results

2026Q3 revenue 0.30, from 0.53 a year earlier. Operating margin -3,423%, from -1,564% a year earlier
Revenue, USD millions
179.1302024Q4 revenue 1.5724Q42025Q1 revenue 1.7625Q12025Q2 revenue 10.7425Q22025Q3 revenue 0.5325Q32025Q4 revenue 1.0525Q42026Q1 revenue 179.1326Q12026Q2 revenue 1.0126Q22026Q3 revenue 0.3026Q3
Operating margin
94.40-3,4232024Q4 operating margin -761.15%24Q42025Q1 operating margin -740.34%25Q12025Q2 operating margin 17.8%25Q22025Q3 operating margin -1,564%25Q32025Q4 operating margin -727.62%25Q42026Q1 operating margin 94.4%26Q12026Q2 operating margin -569.31%26Q22026Q3 operating margin -3,423%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026Q4 E -0.02 per share.
PeriodTypeScaleDateMeanvs prior date
2026Q4Eper share2026-11-10-0.020.0%
2026Q4Rper share2026-11-10-0.020.0%
2026Q4Sper share2026-11-101.000.0%
2026Q3Eper share2026-10-27-0.020.0%
2026Q3Rper share2026-10-27-0.020.0%
2026FYEper share2026-10-260.740.0%
2026FYRper share2026-10-260.740.0%
2026Q3Sper share2026-10-261.000.0%
2026FYS-2026-08-13182.20.0%
2026Q2Sper share2026-07-270.700.0%
2026Q2Eper share2026-06-11-0.02-33.3%
2026Q2Rper share2026-06-11-0.02-33.3%
2026Q1Eper share2026-04-02-0.03-25.0%
2026Q1Rper share2026-04-02-0.03-25.0%
2026Q1Sper share2026-04-020.75+87.5%
2025FYEper share2026-03-04-0.190.0%
2025Q4Eper share2026-03-04-0.030.0%
2025FYRper share2026-03-04-0.190.0%
2025Q4Rper share2026-03-04-0.030.0%
2025FYSper share2026-03-0413.560.0%
2025Q4Sper share2026-03-040.530.0%
2025Q3Eper share2025-10-22-0.030.0%
2025Q3Rper share2025-10-22-0.030.0%
2025Q3Sper share2025-10-201.270.0%
2025Q2Eper share2025-07-28-0.050.0%
2025Q2Rper share2025-07-28-0.050.0%
2025Q2Sper share2025-07-281.590.0%
2025Q1Eper share2025-03-28-0.10+1.5%
2025Q1Rper share2025-03-28-0.10+1.5%
2025Q1Sper share2025-03-281.59-9.8%
2024Q4Sper share2025-03-261.61-2.4%
2024FYEper share2025-03-25-0.390.0%
2024Q4Eper share2025-03-25-0.080.0%
2024FYRper share2025-03-25-0.390.0%
2024Q4Rper share2025-03-25-0.080.0%
2024FYSper share2025-03-256.300.0%
2024Q3Eper share2024-10-15-0.090.0%
2024Q3Rper share2024-10-15-0.090.0%
2024Q3Sper share2024-10-151.860.0%
2024Q2Eper share2024-07-16-0.100.0%
2024Q2Rper share2024-07-16-0.100.0%
2024Q2Sper share2024-07-161.770.0%
2024Q1Eper share2024-02-29-0.11+10.0%
2024Q1Rper share2024-02-29-0.11+10.0%
2024Q1Sper share2024-02-292.71-39.8%
2023FYEper share2024-01-21-0.440.0%
2023FYRper share2024-01-21-0.440.0%
2023FYSper share2024-01-2120.780.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-1.56-1.214-2.888-1.00-0.832-0.46-0.439-0.377-0.1751.1199-
Sales USD millions11667113918614181-
Shares million shares55566590145157170190193-199
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.104-0.066-0.1290.013-0.04-0.020.869-0.0260.296
Sales USD millions122111117910
Shares million shares189190191192192193197198199

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue181.4914.08+128.2%6.17-66.0%18.14-53.5%39.02+255.1%10.99+59.0%6.91+15.0%6.01+1.0%5.95
Cost of Goods Sold Incl. D&A0.040.36-73.9%1.38-1.4%1.40-2.1%1.43-18.3%1.75---
Gross Profit181.4513.72+186.4%4.79-71.4%16.74-55.5%37.59+307.3%9.23---
Selling, General and Administrative Excl. Other36.0040.77-45.5%74.77-21.1%94.77-6.0%100.82+24.6%80.89+30.0%62.21-17.4%75.33+1.9%73.95
Research and Development14.6425.24-53.3%54.04-26.7%73.70-12.7%84.41+28.9%65.50+38.0%47.48-17.6%57.60-0.6%57.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income145.45-27.05-69.97-78.03-63.22-71.65-57.27-71.34-70.19
Interest Expense0.060.10-28.6%0.14-69.6%0.46-73.4%1.73-39.5%2.86-28.7%4.01+90.0%2.11+817.4%0.23
Unusual Expense-1.7111.11+75.0%6.35+8971.4%0.07-96.9%2.23+19.3%1.87+246.3%0.54-99.3%80.16-12.57
Net Income Before Taxes219.91-33.50-69.92-72.85-65.01-76.25-61.20-151.46-61.36
Income Taxes0.000.000.000.00-100.0%4.440.000.00-12.66-4.30
Consolidated Net Income219.91-33.50-69.92-72.85-69.46-76.25-63.75-153.72-57.06
Net Income From Continuing Operations219.91-33.50-69.92-72.85-69.46-76.25-63.75-153.72-57.06
Net Income219.91-33.50-69.92-72.85-69.46-88.39-75.87-164.87-67.15
EPS (Recurring) per share1.10-0.13-0.35-0.44-0.45-0.82-1.00-1.90-1.37
EPS (Basic, Before Extraordinaries) per share1.13-0.17-0.38-0.44-0.46-0.83-1.00-2.89-1.21
EPS (Diluted) per share1.12-0.17-0.38-0.44-0.46-0.83-1.00-2.89-1.21
EBITDA145.49-26.69-68.59-76.63-61.80-69.90-55.29-69.32-68.01
Non-Operating Income (Expense)72.824.76-27.2%6.54+14.5%5.71+163.1%2.17+1569.2%0.13-79.0%0.62-71.2%2.15-3.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.776.95-22.7%8.99-3.3%9.30+64.0%5.67-11.7%6.42+4.2%6.16+23.2%5.00+13.1%4.42
Price To Earnings Ratio ratio statement ratio, not the snapshot3.603.60-------
Price To Sales Ratio ratio5.2665.4498.3522.879.0137.6138.9426.4035.63
Gross Margin %99.9897.4277.6492.2696.3484.05---
Operating Margin %80.14-192.08-1,133.92-430.15-162.03-652.07-828.30-1,186.91-1,180.66
Net Margin %121.17-237.88-1,133.04-401.57-178.01-804.39-1,097.31-2,742.84-1,129.54
Shares Outstanding million shares199.28192.53+1.4%189.96+11.8%169.87+7.9%157.46+8.6%144.99+61.7%89.68+38.4%64.78+16.7%55.52
Market Capitalization798.37798.37+28.8%619.64+47.8%419.24+15.0%364.57-30.7%526.20+74.6%301.43+74.6%172.67-18.8%212.56

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue0.30-43.4%1.01-90.6%179.13+10077.8%1.05-33.1%0.53-60.4%10.74+520.8%1.76+15.0%1.57-27.0%
Cost of Goods Sold Incl. D&A0.010.0%0.010.0%0.01-97.0%0.01-97.0%0.01-97.1%0.01-97.2%0.33-8.3%0.33-8.3%
Gross Profit0.29-44.2%1.00-90.7%179.12+12425.9%1.04-16.1%0.52-48.0%10.73+683.2%1.43+21.2%1.24-30.7%
Selling, General and Administrative Excl. Other10.56+19.9%6.75-23.5%10.00-30.8%8.68-34.2%8.81-52.3%8.82-61.2%14.46-29.0%13.19-40.9%
Research and Development2.62-54.7%2.90-47.3%4.12-54.0%5.01-43.1%5.78-59.5%5.50-64.6%8.96-41.8%8.81-49.8%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.27-5.75-401.0%169.12-7.64-8.291.91-13.03-11.95
Interest Expense0.01-50.0%0.02-33.3%0.02-33.3%0.02-33.3%0.02-33.3%0.030.0%0.03-25.0%0.03-25.0%
Unusual Expense0.22-40.5%0.21-51.2%0.21-98.3%-2.35-218.1%0.37-90.7%0.43+104.8%12.67+6938.9%1.99+765.2%
Net Income Before Taxes59.12-5.14-304.0%169.70-3.76-7.742.52-24.53-12.53
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income59.12-5.14-304.0%169.70-3.76-7.742.52-24.53-12.53
Net Income From Continuing Operations59.12-5.14-304.0%169.70-3.76-7.742.52-24.53-12.53
Net Income59.12-5.14-304.0%169.70-3.76-7.742.52-24.53-12.53
EPS (Recurring) per share0.30-0.03-400.0%0.87-0.03-0.040.01-0.08-0.06
EPS (Basic, Before Extraordinaries) per share0.30-0.03-400.0%0.88-0.02-0.040.01-0.13-0.07
EPS (Diluted) per share0.30-0.03-400.0%0.87-0.02-0.040.01-0.13-0.07
EBITDA-10.26-5.74-399.0%169.13-7.63-8.281.92-12.70-11.62
Non-Operating Income (Expense)69.62+7306.4%0.84-20.8%0.80-33.3%1.55+8.4%0.94-46.3%1.06-41.8%1.20-21.6%1.43-3.4%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.16-3.3%1.60+110.5%1.32+2.3%3.69+126.4%1.20-44.4%0.76-76.1%1.29-35.8%1.63-5.2%
Price To Earnings Ratio ratio statement ratio, not the snapshot3.605.84------
Price To Sales Ratio ratio5.265.224.5965.7659.6138.56103.95100.66
Gross Margin %96.6698.9299.9998.9597.9299.9081.2978.84
Operating Margin %-3,435.79-567.1694.41-727.31-1,567.6717.81-738.49-759.09
Net Margin %19,770.90-507.2094.73-357.37-1,463.5223.49-1,390.36-796.19
Shares Outstanding million shares199.28+3.8%197.63+3.1%196.95+2.9%192.53+1.4%191.95+1.3%191.64+1.5%191.48+6.3%189.96+11.8%
Market Capitalization798.37-8.3%948.18+60.2%879.65+31.6%925.08+49.3%870.31+19.7%591.82+1.5%668.27+44.3%619.64+47.8%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments91.47-25.4%122.62-2.7%126.00-14.2%146.91-5.4%155.32+26.0%123.27+35.7%90.83-27.1%124.62-1.4%126.35
Short Term Receivables1.75-35.4%2.71+13.9%2.38+76.3%1.35+50.0%0.90-31.3%1.31+9.2%1.20-34.1%1.82+109.2%0.87
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.24-37.4%1.98-45.8%3.65+27.2%2.87-35.5%4.45+42.6%3.12+74.3%1.79-35.8%2.79+30.4%2.14
Total Current Assets94.46-25.8%127.32-3.6%132.03-12.6%151.14-5.9%160.66+25.8%127.70+36.1%93.83-27.4%129.23-0.1%129.37
Net Property, Plant & Equipment0.03-99.3%4.36-28.4%6.09-10.6%6.81-15.6%8.07-13.5%9.33-18.2%11.41+12.5%10.14-16.7%12.18
Total Investments and Advances0.000.00-100.0%6.28-83.2%37.36+4.7%35.690.000.00-100.0%22.22+76.3%12.60
Intangible Assets--0.00---0.00-100.0%66.31-20.1%83.01
Other Assets0.13+333.3%0.030.00-100.0%0.10+66.7%0.06+50.0%0.04-86.2%0.290.000.00
Total Assets94.62-28.2%131.71-8.8%144.40-26.1%195.42-4.4%204.49+49.2%137.08+29.9%105.53-53.7%227.91-3.9%237.16
Short Term Debt Incl. Current Port. of LT Debt0.55+14.6%0.48+14.3%0.42+13.5%0.37-2.6%0.38-2.6%0.39+14.7%0.340.000.00
Accounts Payable1.17-49.6%2.32-28.0%3.22-8.5%3.52+11.0%3.17+6.0%2.99+24.6%2.40-24.8%3.19+60.3%1.99
Other Current Liabilities4.29-66.5%12.82-32.0%18.84-34.9%28.96+278.1%7.66+24.4%6.16+21.0%5.09-36.8%8.05-36.3%12.64
Total Current Liabilities6.01-61.5%15.62-30.5%22.49-31.6%32.86+192.9%11.22+17.6%9.54+21.8%7.83-30.3%11.24-23.2%14.63
Long Term Debt3.64-35.3%5.63-32.2%8.30-31.9%12.18-34.3%18.53-16.3%22.15+0.6%22.010.00-100.0%12.00
Provision for Risks Charges0.000.000.000.000.000.000.00-100.0%3.13-70.0%10.42
Deferred Tax Liabilities-------12.66-25.3%16.94
Other Liabilities8.39-35.9%13.09+72.2%7.60-43.8%13.53+155.3%5.30+54.5%3.43+16.3%2.95+353.8%0.65-5.8%0.69
Total Liabilities18.04-47.5%34.34-10.5%38.38-34.5%58.57+67.1%35.05-0.2%35.11+7.1%32.79+18.5%27.67-49.4%54.69
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00-100.0%149.41+8.8%137.28+8.8%126.14+153.4%49.78
Common Equity76.58-21.4%97.37-8.2%106.02-22.5%136.85-19.2%169.44-47.44-64.54-187.1%74.10-44.2%132.69
Total Shareholders Equity76.58-21.4%97.37-8.2%106.02-22.5%136.85-19.2%169.44+66.2%101.97+40.2%72.74-63.7%200.23+9.7%182.47
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity76.58-21.4%97.37-8.2%106.02-22.5%136.85-19.2%169.44+66.2%101.97+40.2%72.74-63.7%200.23+9.7%182.47
Total Liabilities & Stockholders Equity94.62-28.2%131.71-8.8%144.40-26.1%195.42-4.4%204.49+49.2%137.08+29.9%105.53-53.7%227.91-3.9%237.16
Book Value Per Share per share0.40-21.6%0.51-17.7%0.62-28.7%0.87-25.6%1.17-0.53-1.00-175.2%1.33-44.8%2.41
Tangible Book Value Per Share per share0.40-21.6%0.51-17.7%0.62-28.7%0.87-25.6%1.17-0.53-1.00-814.3%0.14-84.4%0.90
Full-Time Employees people19-56.8%44-39.7%73-25.5%98+12.6%87+11.5%78-2.5%800.0%80-38.5%130
Price to Book Ratio ratio9.375.803.512.453.33-6.71-2.792.871.66
Return on Assets %-29.60-50.65-42.88-34.74-44.65-52.55-92.20-24.54-32.90
Return on Equity %-38.52-68.76-59.99-45.35-56.19-72.97-112.63-29.82-43.80
Return on Invested Capital %-41.76-67.88-63.73-46.60-40.56-51.36-162.23-28.50-43.41
Quick Ratio ratio15.738.155.874.6014.3213.3811.9911.508.84
Current Ratio ratio15.738.155.874.6014.3213.3811.9911.508.84

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income217.97-33.50-69.92-72.85-69.46-76.25-63.75-153.72-57.06
Depreciation0.040.36-73.9%1.38-1.4%1.40-2.1%1.43-18.3%1.75-11.6%1.98-2.5%2.03-6.9%2.18
Other Funds (Non Cash)0.433.52-46.0%6.52+74.3%3.74+9.0%3.43-43.1%6.03-39.1%9.90-89.6%95.58-4.43
Funds from Operations218.43-29.61-62.02-67.70-64.60-68.46-51.87-68.78-63.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.67-10.02-2.83-18.23-162.3%29.24+3044.1%0.93+116.3%0.43-2.23-4.28
Cash from Operating Activities219.11-39.64-64.85-85.94-35.36-67.53-51.44-71.01-67.87
Capital Expenditures0.000.00-0.18-1.01-0.51-0.81-0.23-0.59-1.14
Net Assets From Acquisitions0.000.000.000.000.000.00-2.500.00-
Sale of Fixed Assets and Businesses0.360.360.00-100.0%0.020.000.000.00-100.0%0.01-66.7%0.03
Purchase or Sale of Investments-0.9115.22-34.2%23.13-55.3%51.76-74.43-11.87-12.18-142.1%28.92-3.01
Purchase of Investments-90.34-140.06-141.51-80.51-130.43-82.22-85.58-58.76-3.01
Sale Or Maturity of Investments89.43155.28-5.7%164.64+24.5%132.27+136.2%56.00-20.4%70.35-4.2%73.40-16.3%87.680.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.5615.58-32.1%22.95-54.8%50.77-74.94-12.68-14.91-152.6%28.34-4.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock20.865.72-89.0%52.00+69.7%30.65-3.6%31.81-76.8%137.24+58.2%86.75+358.8%18.91-72.0%67.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock20.865.72-89.0%52.00+69.7%30.65-3.6%31.81-76.8%137.24+58.2%86.75+358.8%18.91-72.0%67.65
Proceedsfrom Stock Options-0.000.18-99.6%44.52+46.5%30.39-4.1%31.69-76.5%135.13+56.6%86.30+364.0%18.60-71.9%66.27
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-12.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00-12.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-12.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-100.0%18.550.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities20.865.72-89.0%52.00+69.7%30.65-3.6%31.81-76.8%137.24+58.2%86.75+131.6%37.46-32.7%55.65
Exchange Rate Effect-0.020.01-0.05-266.7%0.03-0.02-300.0%0.01-83.3%0.06-14.3%0.07-1.00
Net Change in Cash239.40-18.32-282.3%10.05-4.49-78.51-237.7%57.03+178.9%20.45-5.14-17.35
Free Cash Flow--39.64-65.03-86.94-35.87-68.34-51.67-71.59-69.00
Preferred Dividends (Cash Flow)-0.000.000.000.00----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-12.66-4.28

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments337.49+260.2%92.62-5.6%95.23-15.5%91.47-25.4%93.70-26.7%98.09-30.9%112.71-12.8%122.62-2.7%
Short Term Receivables1.09-9.9%179.74+15948.2%180.45+12976.1%1.75-35.4%1.21-36.6%1.12-45.9%1.38-49.6%2.71+13.9%
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.98-61.4%1.52-61.1%1.33-51.1%1.24-37.4%2.54-17.5%3.91-6.2%2.72-30.1%1.98-45.8%
Total Current Assets339.57+248.5%273.88+165.6%277.01+137.1%94.46-25.8%97.44-26.6%103.12-30.4%116.81-14.0%127.32-3.6%
Net Property, Plant & Equipment0.00-100.0%0.01-93.3%0.02-88.2%0.03-99.3%0.14-97.0%0.15-97.2%0.17-97.0%4.36-28.4%
Total Investments and Advances0.000.000.000.000.00-100.0%0.00-100.0%0.00-100.0%0.00-100.0%
Intangible Assets-----0.00--
Other Assets0.130.0%0.130.13+333.3%0.13+333.3%0.130.000.030.03
Total Assets339.70+247.7%274.02+165.3%277.16+136.9%94.62-28.2%97.71-30.4%103.27-35.5%117.01-22.1%131.71-8.8%
Short Term Debt Incl. Current Port. of LT Debt0.33-37.7%0.510.0%0.63+12.5%0.55+14.6%0.53+12.8%0.51+13.3%0.56+12.0%0.48+14.3%
Accounts Payable0.32-68.3%0.37-72.0%1.46-34.8%1.17-49.6%1.01-56.3%1.32-50.2%2.24-40.1%2.32-28.0%
Other Current Liabilities241.28+6528.6%2.48-22.3%3.01-81.9%4.29-66.5%3.64-77.4%3.19-83.6%16.63+3.6%12.82-32.0%
Total Current Liabilities241.93+4570.5%3.36-33.1%5.11-73.7%6.01-61.5%5.18-72.6%5.02-77.8%19.43-4.3%15.62-30.5%
Long Term Debt2.98-27.0%3.11-30.7%3.28-34.9%3.64-35.3%4.08-35.1%4.49-35.9%5.04-33.5%5.63-32.2%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities9.04-18.2%8.82-18.2%8.60-35.8%8.39-35.9%11.05+32.5%10.78+34.9%13.39+72.1%13.09+72.2%
Total Liabilities253.95+1150.4%15.29-24.6%16.99-55.1%18.04-47.5%20.31-39.5%20.29-46.0%37.85+6.2%34.34-10.5%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity85.75+10.8%258.73+211.8%260.18+228.7%76.58-21.4%77.40-27.6%82.98-32.2%79.16-30.9%97.37-8.2%
Total Shareholders Equity85.75+10.8%258.73+211.8%260.18+228.7%76.58-21.4%77.40-27.6%82.98-32.2%79.16-30.9%97.37-8.2%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity85.75+10.8%258.73+211.8%260.18+228.7%76.58-21.4%77.40-27.6%82.98-32.2%79.16-30.9%97.37-8.2%
Total Liabilities & Stockholders Equity339.70+247.7%274.02+165.3%277.16+136.9%94.62-28.2%97.71-30.4%103.27-35.5%117.01-22.1%131.71-8.8%
Book Value Per Share per share0.43+7.5%1.31+204.7%1.32+222.0%0.40-21.6%0.40-28.6%0.43-33.8%0.41-35.9%0.51-17.7%
Tangible Book Value Per Share per share0.43+7.5%1.31+204.7%1.32+222.0%0.40-21.6%0.40-28.6%0.43-33.8%0.41-35.9%0.51-17.7%
Full-Time Employees people---19-56.8%---44-39.7%
Price to Book Ratio ratio9.373.6311.3111.9310.497.476.815.80
Return on Assets %100.5581.1381.55-29.60-35.50-41.21-57.29-50.65
Return on Equity %269.5989.5894.73-38.52-45.88-52.82-79.02-68.76
Return on Invested Capital %66.63-1.9664.41-4.68-9.502.88-29.13-12.17
Quick Ratio ratio1.4081.4254.2615.7318.8020.536.018.15
Current Ratio ratio1.4081.4254.2615.7318.8020.536.018.15

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income57.55-5.91-376.2%169.70-3.37-7.812.14-24.53-11.26
Depreciation0.010.0%0.01-50.0%0.01-97.0%0.01-96.8%0.01-97.1%0.02-94.3%0.33-8.3%0.31-8.8%
Other Funds (Non Cash)0.86+13.2%1.34+2580.0%1.05-81.0%-2.82-241.7%0.76-34.5%0.05-97.7%5.54+413.0%1.99+1430.8%
Funds from Operations58.42-4.56-306.3%170.76-6.18-7.042.21-18.66-8.96
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital178.98+14815.0%-1.39-178.87-3494.1%1.961.20-18.47-769.2%5.27-0.18-110.5%
Cash from Operating Activities237.40-5.95-8.11-4.23-5.84-16.26-13.39-9.14
Capital Expenditures0.000.000.000.000.000.000.00-0.08-900.0%
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.00-100.0%0.000.36-0.000.010.000.00
Purchase or Sale of Investments0.50-1.66-110.3%2.20-80.6%-1.94-114.9%-10.2316.08+66.1%11.35-3.7%13.05-39.8%
Purchase of Investments-28.97-23.49-13.80-24.08-51.94-29.61-34.72-40.57
Sale Or Maturity of Investments29.47-29.3%21.82-52.2%16.00-65.3%22.14-58.7%41.71+45.7%45.69+9.1%46.07+23.9%53.62+19.8%
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.50-1.66-110.3%2.20-80.6%-1.59-112.3%-10.2316.09+66.2%11.35-2.9%12.97-40.1%
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock4.57+437.6%3.08+503.9%11.62+318.0%1.59+224.5%0.85-57.1%0.51-97.9%2.78-88.6%0.49-85.8%
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.57+437.6%3.08+503.9%11.62+318.0%1.59+224.5%0.85-57.1%0.51-97.9%2.78-88.6%0.49-85.8%
Proceedsfrom Stock Options-0.09-280.0%-0.000.09-30.8%-0.000.05-86.8%0.00-100.0%0.13-99.4%-0.79-123.0%
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities4.57+437.6%3.08+503.9%11.62+318.0%1.59+224.5%0.85-57.1%0.51-97.9%2.78-88.6%0.49-85.8%
Exchange Rate Effect-0.00-0.00-100.0%-0.010.00-0.010.020.00-0.03-400.0%
Net Change in Cash242.46-4.54-1361.1%5.70+660.0%-4.22-198.4%-15.240.36-98.1%0.75-95.5%4.29-51.5%
Free Cash Flow237.40---4.23-5.84-16.26-13.39-9.22

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Consolidation, Policy-0.04---
License3.9612.60+218.0%89.5%
Non-Cash Royalty2.251.48-34.2%10.5%
Total6.1714.08+128.2%100.0%
Region
Name20242025vs 20242025 share
United States6.1714.08+128.2%100.0%
Total6.1714.08+128.2%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.64%19.9M157.4M4.85M
2026-10-1515.61%24.6M157.4M4.73M
2026-09-3021.62%34.1M157.5M4.25M
2026-09-1511.72%18.5M157.8M3.15M
2026-08-3112.00%18.9M157.6M2.75M
2026-08-1411.73%18.5M157.4M1.98M
2026-07-3112.88%20.2M157.1M1.93M
2026-07-1512.51%19.7M157.1M2.12M
2026-06-3010.89%17.1M157.1M1.94M
2026-06-1511.15%17.5M157.1M1.76M
2026-05-2910.82%17.0M157.0M2.20M
2026-05-1510.47%16.4M157.0M2.18M
2026-04-3011.36%17.7M156.2M2.43M
2026-04-1511.60%17.8M153.4M2.32M
2026-03-3110.59%16.2M152.7M2.24M
2026-03-1310.92%16.4M150.2M2.08M
2026-02-279.82%14.8M150.2M1.58M
2026-02-139.98%15.0M150.2M1.50M
2026-01-309.02%13.6M150.2M1.28M
2026-01-158.69%13.1M150.3M1.14M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.005.000.000.0000.000.000.986-0.0130.000
call1.000.505.000.000.0000.000.000.965-0.0220.000
call1.500.003.100.0011.2200.000.000.948-0.0220.001
call2.000.002.452.347.1841.000.000.929-0.0210.001
call2.500.001.950.005.5040.000.000.903-0.0200.001
call3.000.001.451.254.1544.000.000.865-0.0180.001
call3.500.002.450.005.4420.000.000.795-0.0150.002
call4.000.051.200.150.78037135.000.567-0.0280.002
call4.500.000.050.050.8182530.000.197-0.0090.002
call5.000.000.050.051.2611,1430.000.142-0.0110.001
call5.500.000.050.001.6740.000.000.113-0.0110.001
call6.000.002.050.001.9290.000.000.103-0.0130.001
call7.000.002.050.002.4410.000.000.086-0.0150.001
call8.000.002.050.002.8590.000.000.077-0.0160.001
call9.000.002.050.003.2120.000.000.071-0.0160.001
call10.000.002.050.003.5170.000.000.066-0.0170.001
put0.500.000.050.008.9280.000.00-0.015-0.0120.000
put1.000.004.900.007.3880.000.00-0.036-0.0210.000
put1.500.004.900.005.5110.000.00-0.052-0.0220.001
put2.000.004.900.004.1120.000.00-0.071-0.0210.001
put2.500.004.900.003.0360.000.00-0.097-0.0200.001
put3.000.000.100.051.92116.000.00-0.152-0.0160.001
put3.500.000.250.101.33460.000.00-0.205-0.0140.002
put4.000.000.650.302.86215.000.00-0.433-0.0280.002
put4.500.251.700.006.0380.000.00-0.803-0.0080.002
put5.000.704.901.3531.42921.000.00-0.858-0.0100.001
put5.501.004.900.0020.8390.000.00-0.882-0.0110.001
put6.001.604.900.0016.5840.000.00-0.897-0.0120.001
put7.002.455.000.0011.8680.000.00-0.914-0.0140.001
put8.003.405.800.0011.4490.000.00-0.923-0.0150.001
put9.004.406.600.0011.0030.000.00-0.929-0.0150.001
put10.005.207.700.0011.8520.000.00-0.934-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-128-KCurrent report2026-11-12SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-228-KCurrent report2026-10-20SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-05SCHEDULE 13D/ASEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01SC TO-I/ASEC
2026-09-30SC TO-I/ASEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-04SCHEDULE 13GSEC
2026-08-24SC TO-IIssuer tender offer statementSEC
2026-08-21SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-168-KCurrent report2026-07-15SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-278-KCurrent report2026-05-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY8.96%
Whitefort Capital Management, LP8.00%
BlackRock, Inc.6.97%
Two Seas Capital LP4.11%
Rubric Capital Management LP3.81%
STATE STREET CORP3.57%
VANGUARD CAPITAL MANAGEMENT LLC3.55%
GEODE CAPITAL MANAGEMENT, LLC2.08%
GOLDMAN SACHS GROUP INC1.78%
BANK OF AMERICA CORP /DE/1.34%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.55%
iShares Russell 2000 ETF2.08%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.86%
Morgan Stanley Insight Fund1.38%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Fidelity Small Cap Index Fund0.89%
Inception Portfolio0.82%
iShares Russell 2000 Growth ETF0.75%
EQ/Morgan Stanley Small Cap Growth Portfolio0.66%
iShares Biotechnology ETF0.56%

OakChart. ABUS. Cached 15 minutes. Terms